These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21122646)

  • 1. Should we use apoB for risk assessment and as a target for treatment?
    Brown WV; Myers GL; Sniderman AD; Stein E
    J Clin Lipidol; 2010; 4(3):144-51. PubMed ID: 21122646
    [No Abstract]   [Full Text] [Related]  

  • 2. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
    Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
    J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol.
    Walldius G
    J Intern Med; 2010 Dec; 268(6):549-51. PubMed ID: 21091807
    [No Abstract]   [Full Text] [Related]  

  • 4. Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis.
    Vaverkova H; Karasek D; Novotny D; Jackuliakova D; Lukes J; Halenka M; Frohlich J
    Clin Biochem; 2009 Aug; 42(12):1246-51. PubMed ID: 19450572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
    Walldius G; Jungner I
    J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
    Walldius G; Jungner I
    Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Apolipoproteins are new and better risk indicators of myocardial infarction].
    Walldius G; Jungner I
    Lakartidningen; 2004 Mar; 101(13):1188-94. PubMed ID: 15101244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.
    Rosenson RS; Brewer HB; Ansell B; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR
    Circulation; 2013 Sep; 128(11):1256-67. PubMed ID: 24019446
    [No Abstract]   [Full Text] [Related]  

  • 9. [The apoB/apoA-I ratio is better myocardial infarction marker than lipids].
    Walldius G; Angelin B; Eriksson M
    Lakartidningen; 2006 Mar 8-14; 103(10):751-2. PubMed ID: 16610201
    [No Abstract]   [Full Text] [Related]  

  • 10. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.
    Holewijn S; den Heijer M; Swinkels DW; Stalenhoef AF; de Graaf J
    J Intern Med; 2010 Dec; 268(6):567-77. PubMed ID: 21091808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis].
    Cabezas Castro M; Liem A
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1445-8. PubMed ID: 12908345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of lipids, lipoproteins and apolipoproteins concentrations in cord blood serum of newborns from rural and urban environments.
    Pac-Kozuchowska E
    Ann Agric Environ Med; 2007; 14(1):25-9. PubMed ID: 17655173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
    Davidson MH
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
    [No Abstract]   [Full Text] [Related]  

  • 15. [Semiologic value of LDL cholesterol and apolipoprotein B in risk of atherosclerosis].
    Frey J; Couderc R
    Ann Biol Clin (Paris); 1998; 56(5):517-20. PubMed ID: 9769517
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).
    Williams K; Sniderman AD; Sattar N; D'Agostino R; Wagenknecht LE; Haffner SM
    Circulation; 2003 Nov; 108(19):2312-6. PubMed ID: 14581403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoproteins as markers and managers of coronary risk.
    Chan DC; Watts GF
    QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
    Ballantyne CM
    Am Heart J; 2004 Jul; 148(1 Suppl):S3-8. PubMed ID: 15211326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipids, lipoproteins and apolipoproteins in normal newborns].
    Casanueva V; Cid X; Chiang MT; Molina M; Ferrada MC; Pérez R; Casanueva P
    Rev Med Chil; 1998 Sep; 126(9):1073-8. PubMed ID: 9922510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measurement of apolipoproteins is better than routinely measured traditional lipids].
    Kallner A; Estonius M
    Lakartidningen; 2006 Mar 8-14; 103(10):753-6, 758. PubMed ID: 16610202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.